Arcutis Biotherapeutics (ARQT) Is Up 17.5% After FDA Review Accepted for Pediatric ZORYVE Expansion - Has The Bull Case Changed?

• Arcutis Biotherapeutics recently announced that the FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3%, aiming to expand its approved use in treating plaque psoriasis to children aged 2 to 5 years, with a review decision expected by June 29, 2026.
• This milestone builds on strong product momentum, including multiple industry awards and expanding pediatric studies, signaling wider clinical acceptance and potential for broader market reach in pediatric dermatology.
• We'll now consider how the FDA’s acceptance of ZORYVE’s expanded pediatric application may shape Arcutis Biotherapeutics’ overall investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.

Arcutis Biotherapeutics Investment Narrative Recap

For Arcutis Biotherapeutics, the core investment argument centers on the company’s ability to drive ambitious top-line growth by expanding ZORYVE’s reach across new pediatric and dermatology indications. The FDA’s acceptance of the ZORYVE sNDA for children aged 2 to 5 years is a positive regulatory step, but its impact on short-term revenue growth remains limited until a potential approval, while reliance on ZORYVE still presents the most significant concentration risk for the business. The recent completion of enrollment in the Phase 2 INTEGUMENT-INFANT study evaluating ZORYVE in infants is highly relevant, aligning with the company’s strategy to address unmet needs in pediatric dermatology and reinforcing near-term and future catalysts tied to new indication approvals. By contrast, investors should be aware that heavy dependence on a single product line could potentially...

Read the full narrative on Arcutis Biotherapeutics (it's free!)

Arcutis Biotherapeutics is projected to reach $676.8 million in revenue and $237.0 million in earnings by 2028. This outlook is based on an assumed 37.0% annual revenue growth rate and a $330.3 million increase in earnings from the current level of -$93.3 million.

Uncover how Arcutis Biotherapeutics' forecasts yield a $31.00 fair value, in line with its current price.

Exploring Other Perspectives

Six unique fair value estimates from the Simply Wall St Community for Arcutis Biotherapeutics range from US$18.20 to US$70.13 per share. With the company’s ongoing push for expanded pediatric approvals, you can see how opinions split widely on risks tied to product concentration and market access.

Explore 6 other fair value estimates on Arcutis Biotherapeutics - why the stock might be worth over 2x more than the current price!

Build Your Own Arcutis Biotherapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arcutis Biotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcutis Biotherapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com